Saturday, June 19, 2021

Every cloud has a silver lining...for some


Covid vaccines will substantially benefit a number of pharmaceutical companies.

 The global market for vaccines is worth $70bn (£50bn) this year. Pfizer and Moderna, which are charging $30-plus per person for the required two shots in Europe and the US, will take the lion’s share.

Pfizer and Moderna stand to make tens of billions of dollars from their Covid-19 vaccines this year and next, given G7 governments’ pledge to vaccinate the entire world by the end of 2022.

Pfizer predicted it would make $26bn from its jab in 2021, a third of annual revenue. This was based on orders received by mid-April, so is likely to be an underestimate. Analysts at Morgan Stanley led by David Risinger raised their estimates for Pfizer to $33bn in 2021 and $32bn in 2022, halving to $16.5bn in 2023 and $8.2bn in 2024. Barclays analyst Carter Gould predicts even higher revenues for Pfizer this year – $38bn, falling to about $17bn in 2022, $8.5bn in 2023 and $6.3bn in 2024.

Moderna expects it to generate revenue of $19.2bn, as it aims to produce 1bn doses this year, and up to 3bn doses next year. Barclays analyst Gena Wang forecast slightly higher sales of $19.6bn, falling to $12.2bn in 2022 and about $11bn in each of the following two years. Morgan Stanley analysts have pencilled in $13.5bn next year, falling to $12.5bn in 2023 and 2024.

Johnson & Johnson, which charges the US government $10 per dose for its single-jab vaccine, is likely to generate $6.6bn in revenue this year, according to calculations made by Barclays in March, followed by $1.2bn in 2022 and $383m in 2023.

For AstraZeneca, which charges between $4.30 and $10 for two doses, Barclays forecasts $5.2bn in sales in 2021, falling to $2.3bn and $475m in the next two years.

Other Covid vaccines that could bring in billions of dollars for their makers include the CoronaVac jab developed by China’s Sinovac and the Russian Sputnik V. Nasdaq-listed Sinovac has built factories capable of producing 2 billion doses a year and reported a fourfold increase in sales to $328m between October and December.

  A Novavax report of 90% efficacy after trials in the US and Mexico sent its shares soaring last week. Its chief executive, Stan Erck, talked of “the potential for several billion dollars in revenue in the next 12 months”. Barclays forecasts $7.7bn revenues for Novavax in 2021, falling to $1.8bn and $538m in the next two years.

Covid jabs for billions of humans will earn their makers billions of dollars | Pharmaceuticals industry | The Guardian

No comments: